Botulinum toxin

Ipsen: New Surveys Show Over 80% of Patients with Spasticity and Cervical Dystonia Treated with Botulinum Toxin-A Experience Debilitating Symptom Recurrence

Saturday, May 23, 2020 - 6:00am

The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.

Key Points: 
  • The surveys involved over 400 respondents from five countries, living with spasticity or cervical dystonia and receiving botulinum neurotoxin type A (BoNT-A) injections.
  • Symptom recurrence significantly impacted patients quality of life, including sleep, relationships, performance of daily tasks and working lives.
  • Eligible participants were over 18 years old and had (or cared for someone with) spasticity or cervical dystonia (CD) treated with BoNT-A for at least one year.
  • How do patients with cervical dystonia (CD) experience their botulinum neurotoxin type a (BoNT-A) treatment cycle: results from an international online survey.

Burnett Plastic Surgery’s Mukta Rane Offers Wrinkle-Fighting Injectables

Thursday, May 21, 2020 - 10:41pm

As pointed out by Dr. Carlos Burnett and the Burnett Plastic Surgery team based in New Jersey, dermal fillers and BOTOX are two of the most frequently requested options for restoring youthful-looking, smooth skin.

Key Points: 
  • As pointed out by Dr. Carlos Burnett and the Burnett Plastic Surgery team based in New Jersey, dermal fillers and BOTOX are two of the most frequently requested options for restoring youthful-looking, smooth skin.
  • As of spring 2020, patients can enjoy expanded options for these aesthetic treatments at Burnett Plastic Surgery, where they are excited to announce that in addition to Dr. Burnett, experienced nurse injector Mukta Rane has also started providing dermal fillers as well as BOTOX for patients.
  • In addition to injectables, the practice also offers a wide range of surgical procedures and non-surgical treatments for the face and body.
  • Get to know Dr. Carlos Burnett, Nurse Injector Mukta Rane, and the highly skilled team of staff at New Jerseys Burnett Plastic Surgery .

Revance to Release First Quarter 2020 Financial Results on Thursday, May 7, 2020

Thursday, April 30, 2020 - 9:05pm

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will release first quarter 2020 financial results on Thursday, May 7, 2020 after the close of market.

Key Points: 
  • Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection, today announced that the company will release first quarter 2020 financial results on Thursday, May 7, 2020 after the close of market.
  • A replay of the call will be available beginning May 7, 2020 at 4:30 p.m. PT/7:30 p.m.
  • Revance has successfully completed a Phase 3 program for DaxibotulinumtoxinA for Injection in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc. Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

Facial Injectables: The Next Frontier in On-Demand Beauty Products

Tuesday, March 17, 2020 - 12:30pm

Facial injectables are growing in popularity around the world and are becoming the next frontier in on-demand beauty products.

Key Points: 
  • Facial injectables are growing in popularity around the world and are becoming the next frontier in on-demand beauty products.
  • Botox and fillers have become the most common aesthetic procedures and are the most popular treatments among all classes of people.
  • The easy use, temporary nature, and affordability as compared to other segments are propelling its demand in the beauty industry.
  • Moreover, increasing affordability among Asian consumers and decreasing cost of facial injectables will drive growth in the Asia Pacific facial injectables market.

Revance to Participate in the Barclays Global Healthcare Conference 2020

Tuesday, March 3, 2020 - 9:05pm

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the Barclays Global Healthcare Conference 2020, in Miami, FL.

Key Points: 
  • Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology pioneer focused on innovative aesthetic and therapeutic offerings, including its next-generation neuromodulator product, DaxibotulinumtoxinA for Injection (DAXI), today announced that the company will participate in the Barclays Global Healthcare Conference 2020, in Miami, FL.
  • Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.revance.com .
  • Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    Resilient Hyaluronic Acid and RHA are trademarks of TEOXANE SA.

Evolus to Participate in Barclays 2020 Global Healthcare Conference

Tuesday, March 3, 2020 - 2:00pm

An audio webcast of Evolus presentation will be available on the investor relations section of Evolus website atinvestors.evolus.com.Replays of the webcasts will be available for 90 days after the date of the presentation.

Key Points: 
  • An audio webcast of Evolus presentation will be available on the investor relations section of Evolus website atinvestors.evolus.com.Replays of the webcasts will be available for 90 days after the date of the presentation.
  • Evolusis a performance beauty company with a customer-centric approach focused on delivering breakthrough products.
  • Food and Drug Administrationapproved Jeuveau (prabotulinumtoxinA-xvfs), the first and only neurotoxin dedicated exclusively to aesthetics and manufactured in a state-of-the-art facility using Hi-Pure technology.
  • Jeuveau is a registered trademark of Evolus, Inc.
    Hi-Pure is a trademark of Daewoong Pharmaceutical Co, Ltd.

Facial Injectable Market Size, Share & Trends Analysis Report By Product, By Application, By Region And Segment Forecasts, 2020 - 2027

Thursday, February 27, 2020 - 3:20pm

Facial Injectable Market Size, Share & Trends Analysis Report By Product (Collagen, Hyaluronic Acid, Botulinum Toxin Type A, Calcium Hydroxylapatite, Polymer Fillers), By Application, By Region, And Segment Forecasts, 2020 - 2027

Key Points: 
  • Facial Injectable Market Size, Share & Trends Analysis Report By Product (Collagen, Hyaluronic Acid, Botulinum Toxin Type A, Calcium Hydroxylapatite, Polymer Fillers), By Application, By Region, And Segment Forecasts, 2020 - 2027
    The global facial injectable market size is anticipated to reach USD 21.57 billion by 2027.
  • It is expected to exhibit a 11.8% CAGR during the forecast period, owing to advancements in facial rejuvenation procedures and the increasing importance of medical aesthetics across the globe.
  • Such factors are expected to contribute to the growth of this facial injectables market over the forecast period.
  • Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

Empire Medical Training Launches New Center of Excellence and Innovation™ ‘Comprehensive Botox™ and Dermal Filler Premium Combination Course’ for Practitioners Committed to Excellence

Wednesday, February 12, 2020 - 11:00am

Empire Medical Training, Inc., the premier full-time physician-led nationwide provider of accredited continuing medical education and training workshops for physicians and healthcare professionals, today announced the launch of a new Center of Excellence and Innovation 1-Day Premium Comprehensive Botox and Dermal Filler Combination AMA accredited course for medical and dental practitioners committed to advancing their aesthetic facial treatment expertise.

Key Points: 
  • Empire Medical Training, Inc., the premier full-time physician-led nationwide provider of accredited continuing medical education and training workshops for physicians and healthcare professionals, today announced the launch of a new Center of Excellence and Innovation 1-Day Premium Comprehensive Botox and Dermal Filler Combination AMA accredited course for medical and dental practitioners committed to advancing their aesthetic facial treatment expertise.
  • https://www.empiremedicaltraining.com/memberships/
    This comprehensive course is designed specifically for physicians, nurses, and dentists seeking level 1 Botox and Dermal Filler hands-on training.
  • https://www.empiremedicaltraining.com/calendar/
    For information on the Center of Excellence and Innovation 1-Day Premium Comprehensive Botox and Dermal Filler Combination AMA accredited course, call 1.866.333.6747, or visit www.EmpireMedicalTraining.com .
  • Empire Medical Training provides ongoing medical education in Aesthetics, Anti-aging, Weight Management Medicine, Pain Management, and Surgery.

Botulinum Toxin and Cosmetic Fillers (Children) Bill 2019-20

Friday, February 7, 2020 - 12:02am

House of Commons Library

Key Points: 
  • House of Commons Library

    The Botulinum Toxin and Cosmetic Fillers (Children) Bill 2019-20 was introduced by Laura Trott MP following the Private Members' Bills Ballot on 9 January 2020.

  • First reading took place on 5 February 2020 and the Bill's second reading is due on 15 May 2020.
  • Bill summary

    A Bill to make provision about the administration to persons under the age of 18 of botulinum toxin and of other substances for cosmetic purposes; and for connected purposes.

  • The Public Bill Office (PBO) supports public bill committees.

Revance Announces U.S. FDA Acceptance of Biologics License Application (BLA) for DAXI to Treat Glabellar (Frown) Lines

Thursday, February 6, 2020 - 1:00pm

The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.

Key Points: 
  • The FDA set an action date of November 25, 2020 under the Prescription Drug User Fee Act (PDUFA) VI program.
  • The patient experience has remained largely unchanged since botulinum toxin type A treatments were first introduced over 30 years ago.
  • Revance has successfully completed a Phase 3 program for DAXI in glabellar (frown) lines and is pursuing U.S. regulatory approval in 2020.
  • Revance Therapeutics and the Revance logo are registered trademarks of Revance Therapeutics, Inc.
    BOTOX is a registered trademark of Allergan, Inc.